RxDoctor Payments Data

Luciano Eleazar Lorenzana, MD

Family Medicine · Jacksonville, FLNPI 1346478302

Payments from drug & device makers

$10,731in general payments, 2019–2025

Across 640 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$964
  • Boehringer Ingelheim$942
  • GSK$913
  • Novo Nordisk$913
  • Lilly USA, LLC$789
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$10,703100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,731 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$91,022
Medicare patients
198
Services billed
1,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate33$45,740
RybelsusSemaglutide20$37,931
MounjaroTirzepatide24$32,256
FarxigaDapagliflozin Propanediol36$23,491
EliquisApixaban15$21,348
JardianceEmpagliflozin19$19,309
MyrbetriqMirabegron13$13,841
LinzessLinaclotide11$11,161
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,292
SymbicortBudesonide/Formoterol Fumarate17$4,761
Fluticasone Propionate152$3,084
Rosuvastatin Calcium298$3,006
Arnuity ElliptaFluticasone Furoate12$2,332
Gabapentin98$2,052
Atorvastatin Calcium215$1,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$599$45,74033 claims
Novo NordiskRybelsus$913$37,93120 claims
Lilly USA, LLCMounjaro$789$32,25624 claims
AstraZenecaFarxiga, Symbicort$1,269$28,25353 claims
PfizerEliquis$964$21,34815 claims
Boehringer IngelheimJardiance$942$19,30919 claims
Astellas Pharma US IncMyrbetriq$178$13,84113 claims
AbbVieLinzess$583$11,16111 claims
GSKTrelegy Ellipta, Arnuity Ellipta$913$10,62425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →